The pharmacotherapy management of patients with heart failure with reduced ejection fraction is a populated landscape with multiple drugs affecting morbidity and mortality. Two new medications that are the first in two new classes were approved recently - a neprilysin inhibitor and a hyperpolarization-activated cyclic nucleotide-gated channel blocker.
But first here's a quick table and a few notes about the current use of medications for treating heart failure with reduced ejection fraction.
HughesMedicine - Pharmacotherapy Pearls from the Internal Medicine Clinical Pharmacist
Recommended for you
-
Bleeding risk with anticoagulant and antiplatelet medications is something that we struggle with on a regular basis. Should we fully anti...
-
Let’s start with a patient case. An elderly patient has recently arrived from Italy and you are performing the medication reconciliation f...
-
Ticagrelor is an antiplatelet medication that is commonly used for a number of cardiovascular conditions. Its mechanism is similar to th...
-
The American Geriatrics Society recently published their Alternative Treatments to Selected Medications in reference to the most recent upd...
-
Let’s start with a patient case. A patient is being treated with methylprednisolone 20 mg IV q6 hours for some inflammatory process and...
-
A 74 year old female patient presents to clinic describing dysuria and urinary frequency that started within the last few days. She has ...
-
Midodrine is a peripherally-acting selective alpha1 receptor agonist . Let's take that sentence apart to see what we should expect ...
-
Testing urine for the presence of drugs has a variety of uses including assessing poisoning or overdose, pre-employment testing, substanc...
-
A 55 year old business executive is being discharged from the hospital after a brief admission for cellulitis. His only PMH is HTN and o...
-
Since it's the time of year again when Lyme disease is a concern for patients in many parts of the United States, I thought it would b...
